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Abstract
Background: To report toxicity and early clinical outcomes of hypofractionated simultaneous integrated boost (SIB)
approach with Volumetric Modulated Arc Therapy (VMAT) as adjuvant treatment after breast-conserving surgery.
Methods: Patients presenting early-stage breast cancer were enrolled in a phase II trial. Eligibility criteria: age > 18 years
old, invasive cancer or ductal carcinoma in situ (DCIS), Stage I-II (T < 3 cm and N≤ 3), breast-conserving surgery without
oncoplastic reconstruction. Any systemic therapy was allowed in neoadjuvant or adjuvant setting. All patients
underwent VMAT-SIB technique to irradiate the whole breast and the tumor bed. Doses to whole breast and surgical
bed were 40.5 Gy and 48 Gy, respectively, delivered in 15 fractions over 3 weeks. Acute and late skin toxicities were
recorded. Cosmetic outcome was assessed as excellent/good or fair/poor.
Results: The present study focused on results of a cohort of 144 patients with a minimum follow-up of 24 months
(median 37, range 24–55 months). Median age was 62 years old (range 30–88). All patients had an invasive
carcinoma (no patients with DCIS were present in this subset). At one year, the highest reported skin toxicity was
G1, in 14 % of the patients; this data dropped to 4 % at the last follow-up, after more than 2 years. Breast pain was
recorded in 21.6 % of the patients 6 months after treatment, while it was present in 3.5 % of the patients at the
last follow-up, showing a significant improvement with time. Correlation between liponecrosis and boost target
volume was found not significant. Breast pain was correlated with breast volume. No pulmonary or cardiological
toxicities were recorded. After an early evaluation of clinical outcomes, only one case presented disease relapse, as
liver metastases.
Conclusions: The 3-week VMAT-SIB course as adjuvant treatment after breast-conserving surgery showed to be
well tolerated and was associated with optimal local control. Long-term follow-up data are needed to assess late
toxicity and clinical outcomes.
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Background
Incidence of early stage breast cancer increased in the last
decade thanks to early diagnosis and screening programs.
The treatment approach with breast conserving surgery
(BCS) followed by whole-breast radiotherapy (WBRT)
has been shown to be equivalent to mastectomy in
terms of local control and survival [1–3]. Traditionally,
conventional fractionation schedules for radiotherapy
give 50 Gy in 2 or 1.8 Gy daily fractions, often with an
additional sequential boost to the tumor bed, resulting
in the overall treatment time (OTT) of 6–7 weeks [4].
Recently, there has been a shift in clinical studies to-
ward the delivery of adjuvant radiotherapy using shorter
treatment schedules. Clinical data showed that breast
cancer might present α/β value around 4 Gy similar to
the late-reacting healthy tissues, suggesting the possible
benefit of hypofractionation in breast cancer treatment
[5]. These radiobiological points [6] inspired phase III
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randomized trials comparing standard schedule to dif-
ferent hypofractionated schemes using larger doses per
treatment, resulting in shorter OTT.
All published trials have used schedules involving 13
to 16 treatment sessions to the whole breast over 3 to
5 weeks, with more than 6500 patients enrolled. Ten-year
data from these studies (Royal Marsden trial, Canadian
trial, and the START A and B trials) demonstrated that
hypofractionation is associated to equivalent or improved
outcomes (both local and distant disease control), toxicity,
cosmesis, and cost-effectiveness [7–11]. Moreover, shorter
treatment time results also in greater patient convenience
and resource efficiency.
Consequently, in 2013, the American Society for Radi-
ation Oncology (ASTRO) released a recommendation
to strongly consider the use of shorter treatment sched-
ules in the radiotherapy adjuvant treatment for women
age ≥ 50 years old with early stage invasive breast cancer
after BCS. This is one of the “Choosing Wisely” recom-
mendations, as part of a campaign by the American Board
of Internal Medicine Foundation to encourage the choice
of evidence-based treatments (http://www.choosingwise-
ly.org/clinician-lists/american-society-radiation-oncology-
whole-breastradiotherapy/).
Unfortunately, there are still open issues about the use of
hypofractionated radiotherapy in early stage breast cancer.
Groups most debated are as follows: young patients, pa-
tients with large breasts, patients undergoing chemotherapy
(neoadjuvant or adjuvant). Another unsolved question is
the association with sequential or concomitant boost [12].
As previously specified, ASTRO guidelines recom-
mended hypofractionated radiotherapy only for patients
older than 50 because of a greater risk of local recur-
rence and distant metastases in younger patients. Des-
pite this recommendation, the Canadian trial confirmed
the equivalence in efficacy to prevent local recurrence
for both conventional and hypofractionated schemes among
younger women, that represented the 25 % of the study
population [7]. Moreover, the British agency NICE (National
Institute for Health and Clinical Excellence) considers
schedules of 50 Gy in 25 fractions or 40.05 Gy in 15 frac-
tions as standard radiotherapy regardless of age at diagnosis
[13]. As regards large breast patients, the possible dose het-
erogeneity associated with large breast volumes in a hypo-
fractionation schedule could potentially worsen the cosmetic
outcomes. At last, there are few consistent data concerning
aesthetic results and skin toxicity in patients receiving ei-
ther adjuvant chemotherapy (including agents with known
cardiotoxic effects) or tumour bed boost [14, 15].
Recently, technical developments in radiation oncol-
ogy, such as the use of intensity-modulated radiotherapy,
and breathing-adaptive therapy are ongoing to optimize
the dose distribution for target dose homogeneity and
organs at risk (OARs) sparing.
In this frame, the introduction in the clinical practice
of the volumetric modulated arc therapy (VMAT) tech-
nique which by optimizing multileaf (MLC) shapes,
dose rate and gantry rotation speed [16], allows a gen-
eral improvement of organs at risk sparing, high target
coverage and dose homogeneity, reduced beam-on time
and relative low number of monitor units. In addition,
the breast cancer treatment has been explored for
VMAT delivery [17–20].
Since 2009 the use of VMAT, in its RapidArc form
(Varian, Palo Alto, California, USA) was made available
in our clinical practice for various tumour sites. From
September 2010, an institutional Phase I-II trial on
hypofractionated early stage breast irradiation with sim-
ultaneous integrated boost (SIB) and RapidArc tech-
nique started to recruit patients. The aim of our current
work is to present the early toxicity and cosmetic results
for patients with at least 2-year follow up enrolled in this
prospective Phase I-II trial, who were treated using
VMAT and SIB as adjuvant breast cancer radiotherapy.
Methods
Patients with early-stage breast carcinoma who under-
went conservative surgery were enrolled in an institu-
tional phase I-II prospective non-randomized trial of
adjuvant radiotherapy with SIB delivered with RapidArc
technology (VMAT-SIB). The study received the ap-
proval by the Ethical Review Committee, in compliance
with the Helsinki declaration. Informed consent was ob-
tained from all individual patients.
As per today, 840 patients have been treated according
to the protocol. The primary endpoint of the trial was
the evaluation of the feasibility of VMAT-SIB hypofrac-
tionation. In 2012, data related to the first 50 treated
patients were published [19] proving the technical fea-
sibity, in association with an acceptable acute skin tox-
icity, similar to what was reported in literature. The
secondary endpoint was the evaluation of the toxicity in
terms of acute and late side effects. In the current re-
port, we analysed the results concerning this secondary
endpoint, focusing only on the sub-group of 144 patients
having at least two-year follow-up. The local control was
also reported, even if it was not an explicit objective of
the study.
Protocol eligibility criteria were: age > 18 years old, in-
vasive cancer or ductal carcinoma in situ (DCIS), AJCC
Stage I-II (T-size ≤ 3 cm, N ≤ 3), breast-conserving surgery
without oncoplastic reconstruction, and any systemic
therapy (neoadjuvant or adjuvant). Radiotherapy treat-
ment started within 60 days from the surgery; if adjuvant
chemotherapy was administered, radiotherapy started
after 4 weeks from the last chemotherapy cycle. Patients
with DCIS were made eligible by an amendment to the
protocol since 2013.
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For radiotherapy treatment, all patients were set-up in
supine position, with both arms above the head. CT
dataset was acquired with 3 mm thick adjacent slices.
No respiratory gating was adopted.
The clinical target volume CTV of the whole breast
was the entire mammary gland. CTV of the boost was
the surgical bed, defined by adding 1 cm to the surgical
clips placed in the lumpectomy cavity during surgery.
Three radiation oncologists took part in the contouring,
following common internal delineation guidelines, and
no interobserver variability in the target definition was
here evaluated. Planning target volumes PTV were
contoured by adding a 5 mm margin to each CTV;
PTVs were however limited to 4 mm within the skin
surface, and excluded ribs and lung parenchyma. The
whole breast PTV (PTV_WB) excluded the boost PTV
(PTV_boost).
The treatment dose was prescribed with SIB as
40.5 Gy to the PTV_WB and 48.0 Gy to the PTV_boost,
in 15 fractions over 3 weeks, delivering 2.7 and 3.2 Gy/
fraction to each PTV [19].
Plan objectives were the following: target coverage and
homogeneity: near-to-minimum dose D98% > 95 % for
both PTVs, near-to-maximum dose D2% < 107 % for
PTV_WB. Concerning organs at risk [19]: ipsilateral
lung should receive mean dose <10Gy, and the volume
receiving more than 20Gy should not exceed 10 %
(V20Gy < 10 %); for heart V40Gy < 3 % and V18Gy < 5 %, no
specific requests for mean heart dose; minimize contra-
lateral lung and breast irradiation; ribs maximum dose
not exceeding 50Gy; skin dose not exceeding 40Gy for
cutaneous desquamation: skin dose was recorded for
5 mm thickness of the first skin layers in a region cover-
ing the whole breast plus an additional margin of 3 cm
around the mammary gland.
Plans were optimized for RapidArc delivery, with two
partial arcs in a range from the classical medial tangen-
tial beam to the posterior entrance, through the PTV
side; PRO algorithm was used to modulate MLC shape
and beam intensity during the gantry rotation. The strat-
egy described by Nicolini et al. [21] to have the skin flash
was adopted. Dose calculations used the Anisotropic
Analytical Algorithm (AAA). Delivery was on 6MV beams
from Varian Clinac, Unique or TrueBeam, equipped with
a Millennium MLC-120.
To verify the patient positioning before each treatment
session, daily CBCT (or 2D-2D matching for the patients
treated on Unique linac, not equipped with CBCT)
were acquired; eventual shifts as required by CBCT vs.
planning-CT co-registration were applied.
Patient clinical evaluation was assessed during the
treatment once a week. Follow-up was then scheduled at
the end of radiotherapy, at 1, 3 and 6 months after radi-
ation treatment, and then every 6 months for the first
2 years. Hematologic exams (i.e. CBC, liver and renal
function, tumour marker Ca15.3), as well as breast ultra-
sound were scheduled every 6 months, while bilateral
mammography every 12 months.
Skin toxicity was visually assessed by objective clinical
exam and pictures of the irradiated breast taken in
frontal and lateral views during each visit (during treat-
ment and follow-up). This photographic documentation
was compared with the baseline performed before the
beginning of the radiation treatment; acute toxicity was
scored according to RTOG acute radiation morbidity
scoring criteria, and late toxicity (from 6 month after
RT) according to CTCAE v.4. As late skin toxicity the
main endpoint is the hyperpigmentation; fibrosis and tel-
eangiectasia are also reported. Cosmetic outcomes were
ranked as: excellent/good vs. fair/poor, according to the
Harvard scale [22]. Two observers (a dedicated breast
nurse and a radiation oncologist) always evaluated skin
toxicity. During follow-up visits, the following toxicities
were also assessed: breast pain, as presence or absence,
without differentiating for pain intensity; the presence of
liponecrosis through ultrasound examination was also re-
corded; the lung toxicity was assessed with a thorax radi-
ography requested as part of follow-up every 12 months
and as presence of respiratory symptoms. Heart toxicity
was evaluated only for symptomatic patients.
Dosimetric evaluation was based on DVH analysis of
targets and OARs. Data were reported as mean doses, Vx
(volume receiving more than x dose) and Dy (dose re-
ceived by at least y volume).
Statistical analysis and data correlation was conducted
with the SPSS software (version 21.0). Standard descrip-
tive statistics (mean standard deviation and cross tabula-
tion analysis) was used to describe the data general
behaviour. Univariate analysis was performed to investi-
gate the prognostic role of individual variables, using
ANOVA statistics for correlations with 0.05 as signifi-
cance value.
Results
To date, among the 840 patients treated according to
the phase II protocol, 144 had at least 2-year follow-
up. The results presented in the current work refer
only to this sub-group of patients. All patients have an
invasive carcinoma (no patients with DCIS were
present in this subset due to their late enrolment). The
median follow-up was 37 months (range 24–55
months). Patient characteristics are summarized in
Table 1. In the currently analysed group, four patients
had synchronous bilateral breast treatment. Acute skin
toxicities reported during the treatment course at one,
two, and three weeks, are reported in Fig. 1, where a
maximum of G2 acute toxicity was reported at the
third week of treatment by 8 % of patients. No patient
De Rose et al. Radiation Oncology  (2016) 11:120 Page 3 of 9
Table 1 Patient characteristics
Number of patients 144
Age [years old]
Median [range] 62 [30, 88]
Mean ± SD 60 ± 11
Breast laterality
Left 71 (49.3 %)
Right 69 (47.9 %)
Bilateral 4 (2.8 %)
Performance Status
0 134 (93.1 %)




Ductal infiltrating ca. 123 (85.4 %)
Lobular infiltrating ca. 14 (9.7 %)
Other 5 (3.5 %)
DCIS 0
Unknown 2 (1.4 %)
Grading
G1 16 (11.1 %)
G2 102 (70.8 %)
G3 22 (15.3 %)
Unknown 4 (2.8 %)
ER
ER = 0 6 (4.2 %)
ER > 5 135 (93.8 %)
Unknown 3 (2.1 %)
PgR
PgR = 0 13 (9.0 %)
PgR > 5 128 (88.9 %)
Unknown 3 (2.1 %)
KI67
KI67≤ 20 103 (71.5 %)
KI67 > 20 36 (25.0 %)
Unknown 5 (3.5 %)
cerbB2
Negative 114 (79.2 %)
Positive 19 (13.2 %)
Unknown 11 (7.6 %)
Surgical margins
Negative 128 (88.9 %)
Close 4 (2.8 %)
Positive 1 (0.7 %)
Unknown 11 (7.6 %)
Table 1 Patient characteristics (Continued)
Lesion diameter
≤ 1 cm 39 (27.1 %)
Between 1 and 2 cm 68 (47.2 %)
≥ 2 cm 25 (17.4 %)
Unknown 12 (8.3 %)
pT
1 1 (0.7 %)
1a 4 (2.8 %)
1b 36 (25.0 %)
1c 77 (53.5 %)
1mic 2 (1.4 %)
2 23 (16.0 %)
X 0
is 0
Unknown 1 (0.7 %)
pN
0 122 (84.7 %)
1a 12 (8.3 %)
1sn 5 (3.5 %)
N1(mi) 1 (0.7 %)
X 4 (2.8 %)
Unknown 0
Chemotherapy
Yes 21 (14.6 %)
No 123 (85.4 %)
Hormonotherapy
Yes 120 (83.3 %)
No 24 (16.7 %)
Fig. 1 Acute skin toxicity during the radiotherapy treatment of
three weeks
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with G2 acute toxicity had moist desquamation. No
grade higher than G2 was reported.
Skin toxicity and cosmetic results after the treatment
are shown in Fig. 2 at 1, 3, 6, 12 months after radiother-
apy and at the last follow-up (>24 months, median 37).
One single case of G3 toxicity was recorded at 1-month
follow-up visit. It related to a patient treated for bilateral
breast cancer without chemotherapy, while hormo-
notherapy (tamoxifen and aromatase inhibitors) was ad-
ministered. This high toxicity disappeared at the next
follow-up at 3 months; the same patient developed no
skin toxicity during the treatment. At one year, the high-
est reported skin toxicity was G1, as dermatitis, in 14 %
of the patients, while in 4 % at the last follow-up, show-
ing an almost complete recovery of the morbidity.
A correlation was found between late skin toxicity (re-
corded from 6 months after radiotherapy), as hyperpigmen-
tation, and breast volume receiving 40.5Gy (p < 0.0001).
At one-year follow-up, the group of patients presenting
no skin toxicity had PTV_WB volume of 591 ± 39 cm3,
while in patients presenting mild late toxicity (G1) this
was 1105 ± 98 cm3, i.e. almost doubled. At the last follow-
up, given the small number of G1 toxicity, the correlation
decreased to p = 0.014, keeping however the same trend
(PTV_WB volumes of 646 ± 36 and 1104 ± 198 cm3 for no
and mild toxicity, respectively). As late skin toxicity, no
patients presented fibrosis nor teleangiectasia.
Concerning pulmonary toxicity, diffuse reticular ac-
centuation of the interstitium at chest radiograph was
recorded at the last follow-up in 36 patients (25 % of the
study population). We could consider this radiological
finding as a G1 of pulmonary fibrosis according to
CTCAE v. 4.0, but no further examination as chest CT
was undertaken to confirm the data. No correlation was
found between this feature and the dosimetric results,
and no patients developed respiratory symptoms.
No cases of heart toxicity were recorded until the last
follow-up.
Breast pain was present, at the last follow-up (median
37, range 24–55 months), in 3.5 % of the patients. This
figure changed during follow-up: from 6 to 12, 12 to 24,
24 to 36, and more than 36 months after radiotherapy it
was present in 21.6 %, 12.2 %, 6.2 % and 5.3 % of the
analysed cases, showing an improvement of breast pain
with time.
Liponecrosis, when present, was reported in the
boost region (higher dose/fraction region). It devel-
oped in 23.4 % of the patients (as recorded at last
follow-up). Patients presenting liponecrosis had PTV
boost volume of 48 ± 8 cm3 (as mean ± standard error
of the mean), while it was of 37 ± 4 cm3 for patients
not presenting liponecrosis; correlation between lipo-
necrosis and boost volume was however not statisti-
cally significant.
As clinical outcome, 143 patients (99.3 %) had no
recurrence or metastatic disease. One patient (0.7 %)
developed liver metastases at 39 months from
radiotherapy.
Concerning dosimetric results, in Table 2 a summary
of some parameters related to the main OARs is re-
ported. All the dosimetric objectives were fulfilled. In
the same Table 2 also the dose homogeneity inside the
two targets is presented as standard deviation parameter.
In Fig. 3 a typical dose distribution is shown.
Discussion
The key point of the present study is the clinical applica-
tion of the hypofractionated-SIB scheduling using
VMAT technology in breast treatments, firstly on the
toxicity evaluation.
The large randomized trials on hypofractionation did
not explore the integration of tumour bed boost [7, 9–11].
The Canadian trial [7] had no boost and the UK trials
[9–11] delivered a sequential boost dose increasing in
overall treatment time. Thus, no definitive conclusions
on this issue came from these studies.
Various single-institutional experiences are published
concerning boost association. Two analyses have studied
the association of concomitant boost and the 3-week
course of radiation. Chadha et al. [23] analyzed data
Fig. 2 Skin toxicity and cosmetic outcome after the radiotherapy treatment
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from 160 early breast cancer patients and reported min-
imal acute toxicity (G1 skin effects in 70 % and G2 skin
effects in 5 % of the patients), no late toxicity higher
than G2 (among patients with > 2 years follow-up) and
excellent clinical outcomes at a median follow-up time
of 3.5 years (local relapse-free survival rate was 99 %).
They used field-in-field technique to optimize a total
dose of 40.5 Gy in 2.7 Gy fractions on WB with a con-
comitant boost of 4.5 Gy in 0.3-Gy fractions. Similar re-
sults using a similar treatment scheme were reported by
Formenti et al. [24], analyzing data from 91 patients
treated with IMRT in prone position.
In our experience, the use of SIB revealed optimal
patient compliance, without a significant increase of skin
toxicity or breast pain, as other studies previously
described have confirmed [24–26]. One single case of
G3 toxicity was recorded at 1 month by the end of
treatment and disappeared at 3 months of follow-up.
This good toxicity profile is expected, as with the SIB
technique, differently from sequential boost schemes,
there is no excess dose outside the tumour bed PTV, as
the two dose levels are planned together to be homoge-
neous during the plan optimization. This fact has been
analysed by Franco et al. [27] in their phase II trial with
tomotherapy treatments.
We also evaluated the presence of liponecrosis as re-
corded from ultrasound exam. When present, liponecro-
sis was reported in the boost region (higher dose/
fraction region). To our knowledge, few published pa-
pers report this data, mainly related to the use of Intra-
operative Radiotherapy (IORT) combined to oncoplastic
surgery [28, 29]. In our group of patients, we find no real
correlation between breast pain and liponecrosis, while
an interesting feature was the progressive improvement
of breast pain with time during the follow-up.
To date, there are two large phase III prospective trials
to compare sequential boost vs. concomitant boost. The
RTOG 1005 trial is a phase III prospective trial
Table 2 Dosimetric results, as average ± SD over all patients
Structure Parameter All patients Left side breast patients Right side breast patients
Lung, ipsilateral Mean [Gy] 7.6 ± 1.5 7.5 ± 1.2 7.7 ± 1.7
V20Gy [%] 7.6 ± 2.7 7.4 ± 2.0 7.7 ± 3.2
V5Gy [%] 50.9 ± 14.7 50.2 ± 13.3 51.7 ± 15.9
Lung, contralateral Mean [Gy] 2.5 ± 1.3 2.4 ± 0.9 2.6 ± 1.6
Heart Mean [Gy] 5.1 ± 2.1 6.0 ± 1.6 4.0 ± 2.1
V18Gy [%] 1.3 ± 1.7 2.3 ± 1.8 0.2 ± 0.4
V40Gy [%] 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Breast, contralateral Mean [Gy] 2.3 ± 0.6
Skin Mean [Gy] 22.7 ± 4.3
PTV_boost St.Dev. [Gy] 0.9 ± 1.0
PTV_WB St.Dev. [Gy] 1.5 ± 0.4
Fig. 3 Dose distribution of a typical breast treatment with VMAT-SIB
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comparing conventional radiotherapy (50 Gy in 25 frac-
tions or with hypfractionation option of 42.7 Gy in 16
fractions) followed by a sequential boost of 12–14 Gy in
6–7 fractions vs. a hypofractionated accelerated WBRT
schedule of 40 Gy in 15 fraction with a concomitant
boost to the tumor bed up to 48 Gy in the same 15 frac-
tions. The IMPORT High trial tests dose-escalated RT
delivered with IMRT in early breast cancer patients with
higher than average risk of local recurrence. The stand-
ard arm comprises 40.5 Gy in 15 fractions and a sequen-
tial tumor bed boost of 16 Gy in 8 fractions; as regards
experimental arms, for 15 fractions treatments, the first
arm received fractions of 2.4 Gy, 2.67 Gy and 3.2 Gy to
the whole breast, the index quadrant and the tumour
bed, respectively, while the second arm receives fractions
of 3.53 Gy to the tumour bed [30]. Both these trials have
been closed to accrual and results will provide evidence
on this debated issue.
Recently, Bartelink et al. [31] published mature data
on the eff ect of a radiation boost of 16 Gy on overall
survival, local control, and fibrosis for patients with
stage I and II breast cancer compared with patients who
received no boost. The results support the use of boost
for younger patients confirming a significant improve-
ment in local control (not in overall survival). The rela-
tive benefit of the extra radiation dose for local control
was independent of age, but with increasing age the ab-
solute gain in local control decreased. Therefore, the
authors concluded suggesting the possibility to avoid
boost in most patients older than age 60 years. Not-
withstanding, in the present study we also included pa-
tients over 60 years. Currently, the ideal radiotherapy
approach for ederly patients with low risk early stage
breast cancer is under investigation. Different personal-
ized treatments could be proposed for these patients,
such as Accelerated Partial Breast Irradiation (APBI)
[32], highly hypofractionated schedules (FAST Trial or
FAST-Forward Trial) [33], hormonal therapy only [34],
or surgery without other adjuvant treatments. Surely,
we need a study to compare these different approaches
identifying the best therapeutic strategy for this sub-
group of patients.
Over the past decade, literature data concerning the
use of hypofractionated WBRT in terms of efficacy and
safety have been steadily increasing. In particular, the
analysis of 10-year outcome of START-B trials [11] re-
ported the rate of local tumour relapse of 3.8 % in the
hypofractionated arm compared with 5.2 % in conven-
tional fractionation group. Bane et al. [35] analysed
tumour factors predictive of response to hypofractio-
nated radiotherapy. They concluded that patients with
node-negative breast tumours of all grades and molecu-
lar subtypes (luminal A, luminal B, HER2 enriched and
basal-like) might be safely treated with accelerated
regimens because these features and hypoxia did not
predict response to hypofractionation.
In our study, despite the short follow-up time, we
showed no cases (on 144 patients) of local tumour re-
currence, as the only evidence of disease was a meta-
static expression after more than two years.
Two of the most debated topics about the use of hypo-
fractionation schemes are the association with systemic
therapy (neoadjuvant or adjuvant) and the consequences
of this schedule in young patients. There are some experi-
ences with encouraging but inconclusive results, and we
probably need longer follow-up data to confirm the role of
these schedules especially in young women. In our group
of patients only 11 were less than 45 years old and 21
underwent chemotherapy, for whose toxicities have been
scored similarly to the other analysed patients.
As regards hypofractionation and large breasts we
have more consistent data [36]. Hannan et al. [37] evalu-
ated the effects of breast size on clinical toxicity in hypo-
fractionated WBRT using intensity modulation. Their
schedule had an acceptable toxicity profiles irrespective
of breast size. In our group of patients, we found a cor-
relation between late skin toxicity and the breast volume
receiving 40.5Gy. The difference was evaluated in terms
of G0/G1 skin toxicity, while no grade 2 of skin toxicity
was recorded. One of the main reasons of the radiation
oncologists‘reluctance towards the use of accelerated
schedules is the unknown impact of a higher daily dose/
fraction on late toxicity. Evidence from laboratory and
clinical studies suggests that fraction size has a larger
impact on late effects than acute effects of radiotherapy,
mainly for a potentially increased risk of cardiac or lung
toxicity.
Darby et al. [38], for conventional fractionation schemes,
correlated the risk of ischemic heart disease with dose, es-
timating an increased risk of 7.4 % per Gy of mean heart
dose, knowing that it is related to larger heart volume in-
cluded in the two tangential fields. In our study, by using
VMAT technology, no cardiological events were recorded,
but we did not request particular diagnostic exam to
evaluate cardiological function without clinical manifest-
ation. Although at such short follow-up, the result of no
cardiac events is reassuring. However, it does not guaran-
tee that these patients are not at elevated risk of cardiac
events over a longer follow-up period. A longer follow-up
is needed in this respect.
Few studies investigated pulmonary toxicity in the hypo-
fractionation group. Van Parijs et al. [39] studied the feasi-
bility of a 3-week accelerated schedule for 70 stage I–II
breast cancer patients. Pulmonary function was evaluated
by FEV1 change or DLco; at 2 years, the reduction was
seen greater in patients who had undergone conventional
fractionation compared with hypofractionation arm. Pa-
tients in that study received tomotherapy treatment, i.e. a
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dose distribution inside the lung similar to what is shown
in our present study. Our patients had thorax X-ray exam-
ination every 12 months as part of their follow up
programme. In 25 % of the patients we recorded a diffuse
reticular accentuation of the interstitium. However, no pa-
tients developed pneumonitis nor respiratory symptoms
until the last follow up.
Our study present however two limitations: the rather
short follow-up (at least compared to the time needed to
express very late toxicities), and the quite limited num-
ber or patients. However the results presented here are
encouraging enough to continue in the exploration of
this field. For that reason, it is our goal to continue to
follow this same cohort of patients; they will be re-
evaluated after a longer follow-up, especially focusing on
the heart and lung toxicity, as well as local control.
Conclusion
Hypofractionated VMAT-SIB radiotherapy delivered in
3 weeks showed encouraging 2-years toxicity and clinical
results for early stage breast cancer treatment. A longer
follow-up is needed to confirm these data.
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